In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REGENXBIO Inc.

www.regenxbio.com

Latest From REGENXBIO Inc.

In Vivo’s Quick Guide To Gene Therapy

Once the stuff of (largely implausible) science fiction, gene therapy is now a clinical reality and one that is taking an increasing share of the pharma R&D limelight. In Vivo takes a look at how these therapies work, how the field has emerged and where it is likely to go next.

Gene Therapy Innovation

Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease

Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Deals M & A

Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate

Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.

Deals M & A

IPO Update: Gottlieb’s Resignation Pulls Down Five Of Eight Newly Public Biopharmas

There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • ReGenX Biosciences LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • REGENXBIO Inc.
  • Senior Management
  • Kenneth T Mills, Pres. & CEO
    Vit Vasista, SVP, CFO
    Steve Pakola, MD, SVP, CMO
    Olivier Danos, PhD, SVP, CSO
    Curran M Simpson, SVP, Product Dev. & CTO
    Ram Palanki, PharmD, SVP, Commercial Strategy & Operations
  • Contact Info
  • REGENXBIO Inc.
    Phone: (240) 552-8181
    9600 Blackwell Rd.
    Ste. 210
    Rockville, MD 20850
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register